Evidence map›Paper›PMID 40529365›Full record

ArticleFrontiers in immunology2025

The role of major allergens Art v 1 and Art v 3 in

Nazugum Akhtemova, Akbota Sergazina, Turlan Bolatbekov, Guliza Rakhmatullayeva, Elmira Tailakova, Kairat Tabynov, Gleb Fomin, Lan Zhao, Zhongshan Gao, Kaissar Tabynov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Efficacy and safety ofThe Journal of international medical research · 2026
    Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nazugum Akhtemova *International Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Akbota Sergazina *International Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Turlan BolatbekovInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Guliza RakhmatullayevaInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Elmira TailakovaInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Kairat TabynovInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.
Gleb FominPreclinical Research Laboratory with Vivarium, M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan.
Lan ZhaoCollege of Agriculture and Biotechnology, Zhejiang University, Hangzhou, China.
Zhongshan GaoCollege of Agriculture and Biotechnology, Zhejiang University, Hangzhou, China.
Kaissar TabynovInternational Center for Vaccinology, Kazakh National Agrarian Research University (KazNARU), Almaty, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: This study utilized a BALB/c mouse model to comparatively assess the allergenic potential of Results: Conclusion: These findings establish Art v 1 as the key driver of

Indexed as

AllergensAntigens, PlantArtemisiaAsthmaPollenRhinitis, Allergic, SeasonalAnimalsDisease Models, AnimalFemaleImmunoglobulin ELungMiceMice, Inbred BALB CAllergensAntigens, PlantImmunoglobulin Eallergic asthmaArtemisia pollenArt v 1Art v 3mouse modelpulmonary pathology

Identifiers

PMID40529365
PMCPMC12170315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.